# Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)

> **NCT00909389** · — · COMPLETED · sponsor: **Organon and Co** · enrollment: 4748 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Vytorin (R) (Ezetimibe + Simvastatin)

## Key facts

- **NCT ID:** NCT00909389
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 4748 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909389, "Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00909389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*